Hideo Fukuhara

Dr. Hideo Fukuhara


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
HFHideo Fukuhara
Hideo Fukuhara
KIKeiji Inoue
Keiji Inoue
AKAtsushi Kurabayashi
Atsushi Kurabayashi
MFMutsuo Furihata
Mutsuo Furihata
HFHirofumi Fujita
Hirofumi Fujita
TSTaro Shuin
Taro Shuin

13 November 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HFHideo Fukuhara
Hideo Fukuhara
TNTakahiro Nohara
Takahiro Nohara
KNKoshiro Nishimoto
Koshiro Nishimoto
YHYutaka Hatakeyama
Yutaka Hatakeyama
YHYuki Hyodo
Yuki Hyodo
OSOn Behalf Of The Japan Urological Photodynamic Society
On Behalf Of The Japan Urological Photodynamic Society
Background: To investigate risk factors for orally administered 5-aminolevulinic acid (ALA)-induced hypotension for bladder cancer patients receiving photodynamic diagnosis (PDD)-assisted transurethral resection of bladder tumor (TURBT). Methods: Patients were categorized into two groups intraoperatively: a hypotensive group (minimum systolic blood pressure (SBP) ≤80 mmHg) and a non-hypotensive group (minimum SBP > 80 mmHg). We examined differences between the hypotensive group and non-hypotensive groups to identify clinical risk of ALA-induced hypotension using multivariate logistic regression analysis and decision tree analysis. Results: Among 282 cases with ALA-PDD-assisted TURBT from three institutions who were screened, 245 patients were included in the final analysis. In total, 156 patients (63.7%) showed any grade of hypotension during ALA-PDD-assisted TURBT. General anesthesia and spinal anesthesia were induced intraoperatively in 113 patients (46.1%) and 132 patients (53.9%), respectively. Median SBP at baseline (before taking ALA) and at the beginning of anesthesia was 127 mmHg (range, 69–186 mmHg) and 124 mmHg (range, 69–186 mmHg), respectively. Median minimum SBP during ALA-PDD-assisted TURBT was 75 mmHg (range, 43–140 mmHg). Multivariate logistic regression analysis revealed that history of hypertension (odds ratio (OR) 7.568, p < 0.05) and general anesthesia (OR 14.435, p < 0.05) as significantly associated with an increased risk of hypotension incidence. Use of calcium antagonist showed significant negative associations with hypotension (OR 0.183, p < 0.05). Decision tree analysis showed presence of general anesthesia, age ≥ 74 years and American Society of Anesthesiologists physical status (ASA-PS) ≥2 as the most important discriminators. Conclusions: General anesthesia and hypertension were independent risk factors related to ALA-induced hypotension. In contrast, use of calcium antagonists was identified as a factor associated with reduced risk of ALA-induced hypotension.

10 March 2013 in Cancer Science
Verified
Journal Article
Open access
PDF file
KIKeiji Inoue
Keiji Inoue
HFHideo Fukuhara
Hideo Fukuhara
AKAtsushi Kurabayashi
Atsushi Kurabayashi
MFMutsuo Furihata
Mutsuo Furihata
MTMasayuki Tsuda
Masayuki Tsuda
TSTaro Shuin
Taro Shuin
The purpose of the present study was to investigate the mechanism of photodynamic therapy (PDT) supplemented with exogenously added 5-aminolevulinic acid (ALA) on human urothelial cancer (UC). Moreover, we aimed to determine whether the therapeutic effects of ALA-based PDT (ALA-PDT) for UC could be enhanced by deferoxamine (DFX), an inhibitor of ferrochelatase. The efficiency of ALA-PDT on these cells was analyzed using flow cytometry and the type of cell death was also assessed. The ALA-PDT promoting effect of DFX was examined on both UC cells and human umbilical vein endothelial cells (HUVEC). The ALA-PDT decreased levels of mitochondrial membrane potential and induced cell death mainly via apoptosis in these cells. Moreover, inhibition of ferrochelatase by DFX led to an increase of protoporphyrin IX (PpIX) accumulation and enhanced the effect of ALA-PDT on UC cells. We further investigated the effect of DFX on in vivo PDT with a tumor-bearing animal model and found that DFX efficiently enhanced tumor cell apoptosis. ALA-PDT induced death of neovascular endothelial cells in tumors but did not affect small vessel endothelial cells in normal tissues surrounding the tumor. Furthermore, DFX enhanced inhibition of neovascularization. These results demonstrated ALA-PDT dominantly induced apoptosis over necrosis by direct action on UC as well as via antiangiogenic action on neovacular endothelial cells, suggesting that the therapeutic damage by ALA-PDT could be kept to a minimum in the surrounding normal tissues. In addition, increased accumulation of PpIX by DFX could enhance this effectiveness of ALA-PDT.

1 December 2020 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Open access
SYShinkuro Yamamoto
Shinkuro Yamamoto
HFHideo Fukuhara
Hideo Fukuhara
TKTakashi Karashima
Takashi Karashima
KIKeiji Inoue
Keiji Inoue
5-Aminolevulinic acid (ALA)-mediated photodynamic diagnosis (PDD) has recently been approved in Japan for the management of non-muscle invasive bladder cancer. As such, the current study aimed to investigate the real-world diagnostic accuracy and safety of ALA-PDD-assisted transurethral resection of bladder tumor (TURBT). A total of 76 patients who underwent PDD-assisted TURBT were enrolled. ALA (20 mg/kg body weight) was orally administered before TURBT. Fluorescence observation and tissue collection were performed during surgery, after which diagnostic accuracy was determined. Potential side effects of ALA, including vomiting, hypotension, and liver toxicity, were carefully monitored. The sensitivity, specificity, positive predictive value, and negative predictive value for detecting urothelial carcinoma were 90.1 %, 61.2 %, 55.1 %, and 92.2 % for fluorescence light (FL) and 65.4 %, 88.9 %, 75.7 %, and 83.9 %, for white light (WL) respectively. The mean number of tumors detected per patient was 1.92 and 1.39 for FL and WL (p < 0.05), respectively. No significant differences in the FL sensitivity and specificity were observe among the three patient groups classified according to ALA exposure time after oral administration (2-3, 3-4, and >4 h). ALA-related adverse effects included vomiting (seven cases), hypotension (seven cases, two of which were severe), and liver toxicity (four cases). All side effects disappeared shortly after standard treatment. ALA-PDD showed sufficient diagnostic accuracy even after more than 4 h of ALA exposure prior to surgery, as well as acceptable safety profiles.

9 June 2011 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
HFHideo Fukuhara
Hideo Fukuhara
KIKeiji Inoue
Keiji Inoue
HSHirofumi Satake
Hirofumi Satake
KTKenji Tamura
Kenji Tamura
TKTakashi Karashima
Takashi Karashima
TSTaro Shuin
Taro Shuin

26 May 2020 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HFHideo Fukuhara
Hideo Fukuhara
SYShinkuro Yamamoto
Shinkuro Yamamoto
TKTakashi Karashima
Takashi Karashima
KIKeiji Inoue
Keiji Inoue